Search - tctmd.com

Displaying 481 - 500 of 901

Sort: Relevancy | Date

Presentation TCT 2015

SAPIEN 3: Evaluation of a Balloon-Expandable Transcatheter Aortic Valve in High-Risk and Inoperable Patients With Aortic Stenosis One-Year Outcomes

Presenter: John D. Carroll, Ioanna Kosmidou, Howard C. Herrmann

October 15, 2015

News Conference News TCT 2015

Valve-in-Valve TAVR Benefits Patients with Failing Surgical Bioprosthetic Valves

Todd Neale

October 15, 2015

Presentation TCT 2015

SAPIEN 3: Evaluation of a Balloon-Expandable Transcatheter Aortic Valve in High-Risk and Inoperable Patients With Aortic Stenosis – One-Year Outcomes

Presenter: Howard C. Herrmann

October 15, 2015

News Conference News TCT 2015

Low 1-Year Event Rates Seen After TAVR With Sapien 3

Todd Neale

October 15, 2015

News Industry News

Favorable Results At One Year With Newest Generation Of Balloon-Expandable Transcatheter Aortic Valve In High-Risk And Inoperable Patients With Aortic Stenosis

October 15, 2015

News Industry News

Edwards SAPIEN XT Valve Receives FDA Approval For Aortic Valve-In-Valve Procedures

October 15, 2015

News Industry News

Edwards SAPIEN 3 Valve Demonstrates High Survival And Low Stroke Rate At 1 Year

October 15, 2015

Presentation TCT 2015

FDA-Approved or US IDE Studies: SAPIEN 3 Procedural Considerations and Case Examples

Presenter: Ariel Finkelstein, Ganesh Manoharan, Vinod H. Thourani

October 14, 2015

Presentation TCT 2015

FDA-Approved or US IDE Studies: SAPIEN 3 - Technical Specifications and Clinical Trial Results (CE Studies and PARTNER II S3HR and S3i)

Presenter: Ariel Finkelstein, Ganesh Manoharan, Susheel Kodali

October 14, 2015

Presentation TCT 2015

The Sapien 3 THV: Understanding the New Sizing Algorithm and Deployment Characteristics (With a Case)

Presenter: Susheel Kodali, Jean-Claude Laborde, Vinod H. Thourani

October 14, 2015

Presentation TCT 2015

TCT 102: SAPIEN 3 Implantation in Failed Surgical Aortic Bioprostheses Matched Comparison and Insights From the Valve-in-Valve International Data (VIVID) Registry

Presenter: Michael J. Reardon, Torsten P. Vahl, Moritz Seiffert

October 13, 2015

Presentation TCT 2015

Sapien 3 (Edwards)

Presenter: Samir R. Kapadia, Nicolo Piazza, Torsten P. Vahl

October 13, 2015

News Conference News TCT 2015

Global TAVR Market Poised to Exceed DES Market by 2025

October 11, 2015

News Conference News TCT 2015

Asian TAVR Registry Shows Good Procedural and Clinical Results

October 11, 2015

News Daily News

在人工动脉瓣中二尖瓣运动降低并不少见，但可通过抗凝予以治疗

L.A. McKeown

October 08, 2015

News Daily News

Reduced Leaflet Motion in Bioprosthetic Aortic Valves Not Uncommon But Remedied by Anticoagulation

L.A. McKeown

October 08, 2015

News Daily News

El Menor Movimiento de las Valvas en las Válvulas Aórticas Bioprotésicas es Habitual Pero puede Remediarse con el Uso de Anticoagulación

L.A. McKeown

October 08, 2015

News Daily News

在采用TAVR的早期，在试验中心以外接受治疗的患者的死亡率并非更高

October 01, 2015

News Daily News

In the Early Days of TAVR, No Mortality Penalty for Patients Treated Outside of Trial Centers

October 01, 2015

News Daily News

En los Albores de la TAVR, No Hubo Más Mortalidad en Pacientes tratados en Centros No Participantes en Ensayos

October 01, 2015

Advertisement

SAPIEN 3: Evaluation of a Balloon-Expandable Transcatheter Aortic Valve in High-Risk and Inoperable Patients With Aortic Stenosis One-Year Outcomes

Valve-in-Valve TAVR Benefits Patients with Failing Surgical Bioprosthetic Valves

SAPIEN 3: Evaluation of a Balloon-Expandable Transcatheter Aortic Valve in High-Risk and Inoperable Patients With Aortic Stenosis – One-Year Outcomes

Low 1-Year Event Rates Seen After TAVR With Sapien 3

Favorable Results At One Year With Newest Generation Of Balloon-Expandable Transcatheter Aortic Valve In High-Risk And Inoperable Patients With Aortic Stenosis

Edwards SAPIEN XT Valve Receives FDA Approval For Aortic Valve-In-Valve Procedures

Edwards SAPIEN 3 Valve Demonstrates High Survival And Low Stroke Rate At 1 Year

FDA-Approved or US IDE Studies: SAPIEN 3 Procedural Considerations and Case Examples

FDA-Approved or US IDE Studies: SAPIEN 3 - Technical Specifications and Clinical Trial Results (CE Studies and PARTNER II S3HR and S3i)

The Sapien 3 THV: Understanding the New Sizing Algorithm and Deployment Characteristics (With a Case)

TCT 102: SAPIEN 3 Implantation in Failed Surgical Aortic Bioprostheses Matched Comparison and Insights From the Valve-in-Valve International Data (VIVID) Registry

Sapien 3 (Edwards)

Global TAVR Market Poised to Exceed DES Market by 2025

Asian TAVR Registry Shows Good Procedural and Clinical Results

在人工动脉瓣中二尖瓣运动降低并不少见，但可通过抗凝予以治疗

Reduced Leaflet Motion in Bioprosthetic Aortic Valves Not Uncommon But Remedied by Anticoagulation

El Menor Movimiento de las Valvas en las Válvulas Aórticas Bioprotésicas es Habitual Pero puede Remediarse con el Uso de Anticoagulación

在采用TAVR的早期，在试验中心以外接受治疗的患者的死亡率并非更高

In the Early Days of TAVR, No Mortality Penalty for Patients Treated Outside of Trial Centers

En los Albores de la TAVR, No Hubo Más Mortalidad en Pacientes tratados en Centros No Participantes en Ensayos

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content